ACE2, the kidney and the emergence of COVID-19 two decades after ACE2 discovery

Enrique Lores, Jan Wysocki, Daniel Batlle

Research output: Contribution to journalReview articlepeer-review

13 Scopus citations


Angiotensin-converting enzyme II (ACE2) is a homologue of angiotensin-converting enzyme discovered in 2000. From the initial discovery, it was recognized that the kidneys were organs very rich on ACE2. Subsequent studies demonstrated the precise localization of ACE2 within the kidney and the importance of this enzyme in the metabolism of Angiotensin II and the formation of Angiotensin 1-7. With the recognition early in 2020 of ACE2 being the main receptor of severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2), the interest in this protein has dramatically increased. In this review, we will focus on kidney ACE2; its localization, its alterations in hypertension, diabetes, the effect of ACE inhibitors and angiotensin type 1 receptor blockers (ARBs) on ACE2 and the potential use of ACE2 recombinant proteins therapeutically for kidney disease. We also describe the emerging kidney manifestations of COVID-19, namely the frequent development of acute kidney injury. The possibility that binding of SARS-CoV-2 to kidney ACE2 plays a role in the kidney manifestations is also briefly discussed.

Original languageEnglish (US)
Pages (from-to)2791-2805
Number of pages15
JournalClinical science
Issue number21
StatePublished - Nov 1 2020

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'ACE2, the kidney and the emergence of COVID-19 two decades after ACE2 discovery'. Together they form a unique fingerprint.

Cite this